Oncotype DX Breast Recurrence Score® Test【Financial Assistance Programme & Patient Care Programme】(Limited quotas)

What is the Oncotype DX Breast Recurrence Score® Test?

This is a genomic test performed on a patient’s breast tumor tissue to provide personalized information to help understand whether adding chemotherapy to her treatment regimen is likely to be beneficial.  The tumor specimen is sent to USA lab for testing.


How can the Oncotype DX Breast Recurrence Score® Test results determine the treatment plan?

The test results will provide a Recurrence Score result to determine the treatment plan; a Recurrence Score result between 26 and 100 indicates that the patient is likely to benefit from adding chemotherapy to hormonal therapy. For most patients with a Recurrence Score result of 0 to 25, adding chemotherapy may not lower the risk of recurrence, which means that over-treatment can be avoided. The test results help the doctor determine the most appropriate treatment plan for the patient.


What makes the Oncotype DX Breast Cancer Assay unique compared to other tests?

Clinical research evidence has shown that traditional clinical-pathological features (such as tumor size, grade or clinical risk classification) cannot accurately predict chemotherapy benefit. The Oncotype DX Breast Recurrence Score result is the only validated predictor of chemotherapy benefit, helping to reduce the risks of over-treatment and under-treatment.

According to traditional clinical risk factors, 73% of high clinical risk breast cancer patients had a Recurrence Score of 0-25, suggesting they may have been over treated. 43% of patients classified as low clinical risk had a Recurrence Score of 26-100, indicating they may have been undertreated without the Recurrence Score information.


Who are eligible for the Oncotype DX Breast Recurrence Score® Test?

If you have been recently diagnosed with early-stage invasive breast cancer and meet the following criteria, you may be eligible for the Oncotype DX Breast Recurrence Score®: hormone receptor-positive, human epidermal growth factor receptor 2-negative, and lymph node-negative. If you have positive lymph nodes and the number is no more than 3, you should consult your doctor for more details.


Breast Recurrence Score Test Financial Assistance Programme (Asset-tested)
Breast Recurrence Score Test Patient Care Programme (Non Asset-tested)